Effects of Nefopam on Hyperalgesia After Cardiac Surgery
CompletedPhase 2, Phase 3NCT00413257
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Postoperative pain after major surgery is consecutive not only to the nociceptive inputs coming from the surgical lesion, but also to peripheral and central neuronal sensitization. This lead to postoperative hyperalgesia and allodynia that are enhanced by the per operative use of high opioid doses. Anti-NMDA drugs have been reported as able to reduce this sensitization process and then to decrease acute morphine tolerance during the postoperative period. Nefopam has been lately shown to combine in experimental trials analgesic and anti hyperalgesic effects. The aim of this study is to compare anti-hyperalgesic effects of nefopam given either before incision and continuously for the following 48hours or starting from the end of the surgery and given for 48hours to a control group that would receive placebo for 48hours. Postoperative analgesia will be based on morphine PCA. Pain scores, hyperalgesia, allodynia, postoperative morphine consumption, and development of chronic pain will be the main criteria that will be evaluated during this study
Study details
- Official title
- Study of the Effects of Nefopam on Hyperalgesia Following Sternotomy in Cardiac Surgery
- Conditions
- Hyperalgesia
- Pain, Postoperative
- Pain, Chronic Disease
- Interventions
- Drug: Nefopam
- Drug: néfopam
- Drug: Placebo comparator
- Sponsor
- University Hospital, Bordeaux
- Start date
- 2006-12
- Primary completion
- 2007-12
- Sex
- All
- Age range
- from 55 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 55-75 years old * ASA score: 1-3 * Patients scheduled for Cardiac surgery with median sternotomy for : single valve replacement or Bentall or Benson or Tyron David surgery, single or multiple Cardiac Artery Bypass Grafting (CABG) , combined surgery (valve replacement + CABG) without preoperative risk of postoperative complications * Informed consent obtained from the patient Exclusion Criteria: * Drug or alcohol abuse history * Analgesic or opioid consumption within the 12hs preceding the surgery * Chronic use of analgesic drugs or history of chronic pain * Convulsion or epilepsy history * Glaucoma history * Disability to understand morphine PCA use * Allergy to nefopam
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00413257